奥锐特药业股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为进一步规范奥锐特药业股份有限公司(以下简称"公司")内幕信息管理 行为，加强内幕信息保密工作，维护公司信息披露的公开、公平、公正原则，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办法》《上市 公司监管指引第 5 号——上市公司内幕信息知情人登记管理制度》《上海证券交易所股 票上市规则》《上海证券交易所上市公司自律监管指引第 2 号——信息披露事务管理》 等有关法律、法规及《公司章程》的有关规定，制定本制度。 第二条 本制度所称内幕信息知情人是指根据《证券法》第五十一条规定的，在公 司内幕信息公开前能直接或者间接获取内幕信息的单位和个人。包括但不限于： （一）公司及其董事、高级管理人员； （二）持有公司百分之五以上股份的股东及其董事、监事、高级管理人员，公司的 实际控制人及其董事、监事、高级管理人员； （三）公司控股或者实际控制的公司及其董事、监事、高级管理人员； （四）由于所任公司职务或者因与公司业务往来可以获取公司有关内幕信息的人员； （五）公司收购人或者重大资产交易方及其控股股东、实际控制人、董事、 ...

奥锐特药业股份有限公司 累积投票制实施细则 第一章 总 则 第一条 为进一步完善奥锐特药业股份有限公司(以下简称"公司")法人治理结构， 保证公司所有股东充分行使权利，根据《中华人民共和国公司法》（以下简称《公司法》） 《中华人民共和国证券法》《上市公司治理准则》《上市公司章程指引》《上市公司股 东会规则》《奥锐特药业股份有限公司章程》（以下简称《公司章程》）等法律、法规、 规范性文件及公司治理文件等的有关规定，特制定本实施细则。 第二条 本实施细则所指累积投票制，是指公司股东会选举两名以上的董事时采用 的一种投票方式。即公司股东会选举董事时，股东所持的每一有效表决权股份拥有与该 次股东会应选董事总人数相等的投票权，股东拥有的投票权等于该股东持有股份数与应 选董事总人数的乘积。股东既可以用所有的投票权集中投票选举一位候选董事，也可以 将投票权分散行使、投票给数位候选董事，最后按得票多少依次决定当选董事。 第三条 本实施细则所称"董事"包括非独立董事和独立董事。由职工代表担任的 董事由公司职工民主选举产生或更换，不适用于本实施细则的相关规定。 第四条 公司通过累积投票制选举产生的董事，其任期不实施交错任期制，即 ...

奥锐特药业股份有限公司 防止大股东及关联方占用公司资金管理制度 第一章 总 则 第一条 为了维护奥锐特药业股份有限公司(以下简称"公司")、公司全体股东及 公司债权人的合法利益，杜绝大股东及关联方占用公司资金行为的发生，根据《中华人 民共和国公司法》《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管 要求》 (一)经营性资金占用:指控股股东及关联方通过采购、销售、相互提供劳务等生产 经营环节的关联交易产生的资金占用。 (二)非经营性资金占用:指公司为控股股东及关联方垫付各种款项；公司为控股股 东及关联方以有偿或无偿的方式，直接或间接地拆借资金；公司为控股股东及关联方代 偿债务；控股股东不及时偿还公司承担对其的担保责任而形成的债务；及其他在没有商 品和劳务对价情况下，公司提供给控股股东及关联方使用资金；公司与控股股东及关联 方互相代为承担成本和其他支出等。 第四条 纳入公司合并会计报表范围的子公司与公司控股股东及关联方之间进行的 资金往来适用本制度。 第二章 防止控股股东及关联方的资金占用 第五条 公司与控股股东及关联方发生的关联交易必须严格按照《公司章程》、《关 联交易管理办法》等进行决策和实施 ...

奥锐特药业股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为规范奥锐特药业股份有限公司（以下简称"公司"）董事、高级管理人 员的薪酬管理，建立科学有效的激励与约束机制，有效调动公司董事、高级管理人员的 工作积极性，提高公司的经营管理效益，根据《公司法》《证券法》等有关法律、法规 以及《公司章程》等规定，特制定本薪酬管理制度。 第二条 适用本制度的董事是指本制度执行期间公司董事会的全部在职成员。其中， 董事由内部董事、外部董事和独立董事构成。 （一）内部董事：是指与公司之间签订聘任合同或劳动合同的公司高级管理人员或 其他员工兼任的董事。 （二）外部董事：是指不在公司担任除董事外的其他职务的非独立董事。 （三）独立董事：是指公司按照《上市公司独立董事管理办法》的规定聘请的董事。 第三条 适用本制度的高级管理人员包括总经理、财务负责人、董事会秘书、副总 经理以及《公司章程》规定的其他高级管理人员。 第四条 董事、高级管理人员薪酬与公司经营业绩和股东利益相结合，保障公司稳 定发展，同时符合市场价值规律，薪酬制度遵循以下原则： （一）公司提供的薪酬与市场同等职位收入水平相比有竞争力的原则； （四）短 ...

Core Viewpoint - Rundu Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved operating revenue of 548 million yuan, representing a year-on-year decrease of 8.22% [1] - The net profit attributable to shareholders of the listed company was -36.19 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -44.84 million yuan [1] - The basic earnings per share were -0.11 yuan [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth, with a 10.67% year-on-year increase in revenue for the first half of 2025, reaching 1.512 billion yuan, and a net profit of 291 million yuan, up 2.57% year-on-year [5] - The company is actively enhancing its innovation pipeline, including the acquisition of the antibacterial peptide new drug JIJ02 gel for 90 million yuan, which is currently in clinical phase I and aims to treat common acne [6] - The company is undergoing a product structure adjustment, leading to revised profit forecasts for 2025-2027, with expected net profits of 570 million, 642 million, and 731 million yuan respectively [5] Financial Summary - For the first half of 2025, the gross margin was 74.58%, an increase of 1.44 percentage points, while the net margin was 19.27%, a decrease of 1.53 percentage points [5] - The company’s revenue from drug formulations in the first half of 2025 was 1.247 billion yuan, reflecting a 14.86% increase, with strong sales of products like Loxoprofen sodium gel patches [5] - The projected earnings per share (EPS) for 2025-2027 are 1.14, 1.28, and 1.46 yuan per share, with corresponding price-to-earnings (P/E) ratios of 16.2, 14.4, and 12.6 times [5][8]

Core Viewpoint - Jiuzhou Pharmaceutical announced a capital increase of 200 million yuan for the construction of an innovative drug CDMO production base in Taizhou, with the project being implemented by Jiuzhou Pharmaceutical (Taizhou) Co., Ltd. [1] Group 1 - The company will hold the 16th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on August 5, 2025 [1] - The capital increase is aimed at supporting the first phase of the construction project [1] - Jiuzhou Pharmaceutical (Taizhou) has completed the business registration change and obtained a new business license from the Market Supervision Administration of Linhai City [1]

Core Viewpoint - The company, Anglikang, reported a revenue of 724 million yuan in the first half of 2025, with significant contributions from its formulation, API, and specialty intermediates businesses, indicating a positive growth trajectory despite market fluctuations [1][2]. Financial Performance - In H1 2025, the company achieved revenues of 315 million yuan from formulations, 288 million yuan from APIs, and 90.12 million yuan from specialty intermediates, with gross margins of 46.67%, 21.94%, and 70.20% respectively [1]. - The company's R&D investment reached 85.6 million yuan, accounting for 11.82% of its revenue, highlighting its commitment to innovation [1][4]. Business Structure and Market Strategy - The company maintains a diversified business structure, with domestic sales accounting for 75.85% and international sales for 24.15%, focusing on large pharmaceutical and feed enterprises [2]. - Through a combination of direct sales and deep distribution, the company has established a stable market foundation in the chemical API and formulation sectors [2]. R&D and Innovation - The company is advancing its innovation strategy, with multiple new drug projects entering clinical stages, including ALK-M001/BM2216 and ALK-N001/QHL-1618 [1][4]. - In H1 2025, the company secured four invention patents and five utility model patents, reflecting its strong focus on R&D [4]. Strategic Collaborations - The company signed a licensing agreement with Yafei Biopharmaceutical and Qinhuli Biopharmaceutical to develop the innovative drug ALK-N002/IMD-1005, which targets CD47 for cancer treatment [5][6]. - This collaboration aims to enhance the company's product portfolio in the oncology sector, leveraging unique drug design for improved therapeutic outcomes [6][7]. Market Expansion in Emerging Sectors - The company is actively expanding into the pet medicine and nutrition market, which is projected to grow significantly, with the pet medicine market expected to increase from 9.39 billion yuan in 2020 to 20.95 billion yuan by 2024, reflecting a compound annual growth rate of 22.2% [8]. - The company has made progress in its pet medicine R&D projects, completing several product registrations and enhancing market recognition through initiatives like the "Angmai Cup" veterinary anesthesia case competition [8]. Future Outlook - Anglikang aims to continue its growth trajectory by integrating resources to optimize product layout and transitioning from a focus on generic drugs to a model that includes specialty generics, modified new drugs, and innovative drugs [9]. - The company is committed to sustainable development and enhancing its brand recognition in the modern pharmaceutical industry [9].

国金证券股份有限公司 关于江苏吉贝尔药业股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 国金证券股份有限公司（以下简称"国金证券" "保荐机构"）作为江苏吉贝 尔药业股份有限公司（以下简称"吉贝尔" "公司"）的保荐机构和持续督导机构， 根据中国证监会出具的《关于同意江苏吉贝尔药业股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2024〕843 号），同意公司以简易程 序向特定对象发行股票 744.6889 万股，每股面值 1.00 元，每股发行价格为 币 9,687,596.06 元（不含税）,募集资金净额为人民币 188,474,120.23 元。信 永中和会计师事务所（特殊普通合伙）对公司本次发行新股的资金到位情况进行 了审验，并于 2024 年 6 月 17 日出具了《验资报告》（XYZH/2024SHAA2B0118 号）。 公司依照规定对募集资金采取了专户存储管理，并与保荐机构、募集资金专 户监管银行签订了募集资金三方监管协议。 二、本次使用暂时闲置募集资金进行现金管理的情况 根据《证券发行上市保荐业务管理办法》 《上海证券交易所科创板股票上市规则》 《上市公司募集资金监管规则》 ...

Group 1 - The company plans to repurchase A-shares with a budget of 10 million to 20 million yuan, with a maximum repurchase price of 9.53 yuan per share, over a period of 12 months [1] - As of July 31, the company has repurchased 265,500 shares, accounting for 0.10% of the total share capital, with a total expenditure of 1.9674 million yuan [1] - The company has received a commitment for a 16.2 million yuan stock repurchase special loan from China Merchants Bank, with a term of 36 months, to support the repurchase [1] Group 2 - The company will repurchase shares based on market and funding conditions and will disclose the information in a timely manner [1] - Investors are reminded to pay attention to risks associated with the repurchase plan [1]